Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial

OBJECTIVES: To evaluate the efficacy and safety of efalizumab in continuous or interrupted therapy of adults with moderate-to-severe plaque psoriasis who had failed to respond to or were intolerant of other systemic therapies, including methotrexate, ciclosporin and psoralen plus UVA phototherapy, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotti, Torello, Chimenti, Sergio, Katsambas, Andreas, Ortonne, Jean-Paul, Dubertret, Louis, Licu, Daiana, Simon, Jan
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Inc 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855833/
https://www.ncbi.nlm.nih.gov/pubmed/20428228
http://dx.doi.org/10.1111/j.1753-5174.2009.00026.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855833/
https://www.ncbi.nlm.nih.gov/pubmed/20428228
http://dx.doi.org/10.1111/j.1753-5174.2009.00026.x

Ejemplares similares